1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsMassachusetts Life Sciences Center (MLSC) Grants is sponsored by Massachusetts Life Sciences Center. Provides grants and loans to biotech and medical device companies in Massachusetts to support innovation and commercialization.
Get alerted about grants like this
Get emailed when new opportunities from “Massachusetts Life Sciences Center” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →According to the current listing, eligibility includes: Biotech and medical device companies in Massachusetts. Confirm the full requirements in the official notice before applying.
Massachusetts Life Sciences Center (MLSC) Grants is funded by Massachusetts Life Sciences Center. Verify program details on the funder's official page before applying.
This opportunity targets applicants in Massachusetts. If your organization operates elsewhere, check the official notice for location requirements.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
Past winners and funding trends for this program
Awards slashed by half, life sciences applicants rejected at 95%, and the White House steering which fields get funded. How the GRFP went from funding the person to funding the priority.
Read articleAfter a rare gap with zero active omnibus NOFOs, NIH has reissued its SBIR/STTR parent announcements — collapsing four solicitations into two, adding a Strategic Breakthrough bridge and a Commercialization Readiness Pilot, and reopening the funnel with a September 5, 2026 receipt date. Here are the exact solicitation numbers, the new budget ceilings, what actually changed, and how a small business should sequence its submission.
Read articleAfter an authorization lapse froze new SBIR/STTR awards for five months, NIH reopens its submission window on August 5, 2026, with a first standard deadline of September 8. Phase I awards run to $323,090, Phase II to $2,153,927, with published waiver topics reaching $700,000 and $3 million — and a new Phase IIB Strategic Breakthrough lane up to $30 million. Here is how the restarted omnibus is structured, why applying early matters more than usual this cycle, and how to position a life-science startup to win.
Read article